🔗 Share this article

While America proceeds with unprecedented adjustments to its immunization recommendations, one figure has surfaced unexpectedly: Høeg, a US-based physician and epidemiologist who rose to prominence by questioning Covid vaccines throughout the global health crisis and has concentrated on possible deaths after Covid immunization in her recent time at the Food and Drug Administration.

Planned Shifts to Pediatric Vaccine Schedule

Health officials planned to announce radical revisions to the childhood vaccination calendar recently, synchronizing the US with the Danish national calendar, according to reports – a major change that would place the US out of alignment with much of the international standard with little proof for benefit. The announcement has been pushed back until the new year.

Rather than Vinay Prasad, Tracy Beth Høeg is scheduled to address the audience at the event. She was recently named temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the division this year.

Consolidating Power at the Agency

This interim role may indicate a closer partnership between the drug and vaccine branches as Dr. Høeg and Prasad solidify control at the regulatory agency – and it signals a renewed priority upon rolling back already-approved immunizations at the FDA.

Dr. Høeg has often pushed for ending specific childhood vaccine recommendations in the US in order to be more similar to Denmark, a society with comprehensive healthcare and a population approximately the size of Wisconsin’s.

To date public appearances, she has continued to focus on vaccines – typically the responsibility of Dr. Prasad, head of the FDA’s CBER – instead of drug regulation.

Doubts Over Background

Dr. Høeg has no obvious track record in drug development, oversight or administrative roles, which has been customary for former heads of the Center for Biologics Evaluation and Research. She has worked at the FDA as a senior adviser to the agency head and CBER since March.

“It seems she lacks to have the necessary background” for leading the drug-regulation department, remarked Dr. Jonathan Howard. “She’s never run a clinical trial. She lacks experience in managing a large organization. She lacks background in drug approvals.”

Past directors of CBER would “be deeply familiar with laws and regulations and the underlying principles of medication creation”, noted Dr. Janet Woodcock. “Frankly, she has not acquired the type of experience that previous people who headed the center have had.”

CDER has an immense workload at the FDA, the former commissioner pointed out.

“Everybody just pays attention on the new drug program, but the generic program approves a multitude of generic medications. There is also a biologic copycat branch, over-the-counter program and so forth, and all of those must be supervised,” she said. “The area you don’t keep your eye on, that is the part that I always told people is going to cause problems.”

There is also, a major management component to the role, which manages more than 5,000 staff members. “It’s a huge management job, if you execute it properly,” Woodcock added.

Agency Reaction and Disputed Programs

When asked about concerns about Høeg’s qualifications and whether this assignment signifies more teamwork among FDA leaders on vaccines, a representative responded that the “concerns are based on inaccurate presumptions”.

“Her experience matches the duties of her role,” the spokesperson said, noting the time Dr. Høeg spent guiding the FDA commissioner on “drug safety and oversight research, including predictive safety algorithms and vaccine surveillance”.

As the temporary head, Høeg assumes responsibility for the commissioner’s controversial priority voucher program, a disputed rapid therapy clearance system that allegedly concerned her predecessors. “How are these drugs being chosen for this fast-track system? Who makes the decisions?” Howard said. “There is a lot of lack of transparency occurring at the FDA right now.”

In general, he said, “the FDA seems to be moving towards laxer rules of pharmaceuticals, except for immunizations.”

Established Track Record on Vaccines

With immunizations, Dr. Høeg has a clearer, if concerning, past, some experts have noted. She authored a analysis using unverified volunteer-provided data to determine the rate of myocarditis following Covid immunization. She counseled the Florida surgeon general Dr. Joseph Ladapo, who allegedly have changed statistics to suggest COVID-19 vaccines are more dangerous than they are.

Part of her “policy goals” for the new federal leadership encompassed altering guidelines for new vaccines and halting “non-essential” vaccines, she stated post-election on a audio program. At the agency, Høeg has according to sources floated the idea of excluding teenage boys from getting Covid vaccines.

“She is an complete dogmatist who commences with her conclusions and tailors the evidence to fit the evidence in a highly disingenuous, untruthful manner,” Howard stated.

Consolidating Power and a “Revenge Tour”

Dr. Høeg became part of other contrarians, {like|